VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2014 | Phase III study shows brentuximab improves progression-free survival in Hodgkin lymphoma

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, New York, NY) presents results from the phase III AETHERA trial, which evaluated the safety and efficacy of brentuximab vedotin in preventing post-autologous stem cell transplant disease recurrence in Hodgkin lymphoma patients.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter